LIMERICK BIOPHARMA

pharmaceutical preparations for the treatment of Tangiers disease, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cystic fibrosis, human immunodeficiency virus (HIV), diabetes, hyperlipidemia, cancer, atherosclerosis, hypertension, insulin resistance, dyslipidemia, and hepatic cholestasis; pharmaceutical preparations for the treatment of the metabolic system, the central nervous system, the peripheral nervous system, the liver, the immune system, the renal system, and the cardiovascular system; pharmaceutical preparations for the treatment of metabolic diseases and disorders, infectious diseases, autoimmune diseases and disorders, inflammatory disorders, and cardiovascular disease; pharmaceutical preparations for the treatment of renal diseases, disorders and dysfunction; pharmaceutical preparations for the prevention and treatment of organ rejection; pharmaceutical preparations for use in tissue and organ transplantation, for adjuvant use in tissue and organ transplantation, for use in oncology, and for use in chemotherapy; pharmaceutical preparations and substances for the treatment of viral related diseases and disorders, and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of pain; pharmaceuticals, namely, anti-infectives, immunosuppressants, anti-inflamatories, and antivirals; analgesic pharmaceutical preparations; anti-diabetic pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals